152 related articles for article (PubMed ID: 12394765)
1. Urinary interleukin-8 predicts the response of standard and low dose intravesical bacillus Calmette-Guerin (modified Danish 1331 strain) for superficial bladder cancer.
Kumar A; Dubey D; Bansal P; Mandhani A; Naik S
J Urol; 2002 Nov; 168(5):2232-5. PubMed ID: 12394765
[TBL] [Abstract][Full Text] [Related]
2. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.
Thalmann GN; Sermier A; Rentsch C; Möhrle K; Cecchini MG; Studer UE
J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941
[TBL] [Abstract][Full Text] [Related]
3. The impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial.
Gontero P; Oderda M; Mehnert A; Gurioli A; Marson F; Lucca I; Rink M; Schmid M; Kluth LA; Pappagallo G; Sogni F; Sanguedolce F; Schiavina R; Martorana G; Shariat SF; Chun F
J Urol; 2013 Sep; 190(3):857-62. PubMed ID: 23545101
[TBL] [Abstract][Full Text] [Related]
4. Urinary interleukin-8/creatinine level as a predictor of response to intravesical bacillus Calmette-Guerin therapy in bladder tumor patients.
Rabinowitz R; Smith DS; Tiemann DD; Hudson MA
J Urol; 1997 Nov; 158(5):1728-31; discussion 1731-2. PubMed ID: 9334588
[TBL] [Abstract][Full Text] [Related]
5. Urinary interleukin-2 may predict clinical outcome of intravesical bacillus Calmette-Guérin immunotherapy for carcinoma in situ of the bladder.
Watanabe E; Matsuyama H; Matsuda K; Ohmi C; Tei Y; Yoshihiro S; Ohmoto Y; Naito K
Cancer Immunol Immunother; 2003 Aug; 52(8):481-6. PubMed ID: 12707736
[TBL] [Abstract][Full Text] [Related]
6. Sufficient prophylactic efficacy with minor adverse effects by intravesical instillation of low-dose bacillus Calmette-Guérin for superficial bladder cancer recurrence.
Irie A; Uchida T; Yamashita H; Matsumoto K; Satoh T; Koh H; Shimura S; Iwamura M; Baba S
Int J Urol; 2003 Apr; 10(4):183-9. PubMed ID: 12657096
[TBL] [Abstract][Full Text] [Related]
7. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials.
Sylvester RJ; van der MEIJDEN AP; Lamm DL
J Urol; 2002 Nov; 168(5):1964-70. PubMed ID: 12394686
[TBL] [Abstract][Full Text] [Related]
8. Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer.
Shepherd AR; Shepherd E; Brook NR
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012112. PubMed ID: 28268259
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-8 expression in the urine after bacillus Calmette-Guerin therapy: a potential prognostic factor of tumor recurrence and progression.
Thalmann GN; Dewald B; Baggiolini M; Studer UE
J Urol; 1997 Oct; 158(4):1340-4. PubMed ID: 9302115
[TBL] [Abstract][Full Text] [Related]
10. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
Librenjak D; Situm M; Eterovic D; Dogas Z; Gotovac J
Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of urinary interleukin-8 cutoff point for recurrences after transurethral resection plus induction bacillus Calmette-Guérin treatment in non-muscle-invasive bladder tumors.
Sagnak L; Ersoy H; Ozok U; Senturk B; Ercil H; Bahar G; Ozturk E
Clin Genitourin Cancer; 2009 Aug; 7(2):E16-23. PubMed ID: 19692317
[TBL] [Abstract][Full Text] [Related]
12. Intravesical versus intravesical plus intradermal bacillus Calmette-Guerin: a prospective randomized study in patients with recurrent superficial bladder tumors.
Lüftenegger W; Ackermann DK; Futterlieb A; Kraft R; Minder CE; Nadelhaft P; Studer UE
J Urol; 1996 Feb; 155(2):483-7. PubMed ID: 8558641
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the Fluorescence In Situ Hybridization Test to Predict Recurrence and/or Progression of Disease after bacillus Calmette-Guérin for Primary High Grade Nonmuscle Invasive Bladder Cancer: Results from a Prospective Multicenter Trial.
Lotan Y; Inman BA; Davis LG; Kassouf W; Messing E; Daneshmand S; Canter D; Marble HT; Joseph AM; Jewell S; Boorjian SA
J Urol; 2019 Nov; 202(5):920-926. PubMed ID: 31120373
[TBL] [Abstract][Full Text] [Related]
14. [Results of adjuvant intravesical Bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer].
Yumura Y; Oogo Y; Takase K; Hamano A; Yamashita Y; Noguchi S; Satomi Y
Hinyokika Kiyo; 2004 Nov; 50(11):767-71. PubMed ID: 15628536
[TBL] [Abstract][Full Text] [Related]
15. Long-term efficacy of intravesical bacillus Calmette-Guerin for carcinoma in situ: relationship of progression to histological response and p53 nuclear accumulation.
Ovesen H; Horn T; Steven K
J Urol; 1997 May; 157(5):1655-9. PubMed ID: 9112499
[TBL] [Abstract][Full Text] [Related]
16. Intravesical instillation therapy with bacillus Calmette-Guérin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guérin immunotherapy.
Shintani Y; Sawada Y; Inagaki T; Kohjimoto Y; Uekado Y; Shinka T
Int J Urol; 2007 Feb; 14(2):140-6. PubMed ID: 17302571
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients.
Yossepowitch O; Eggener SE; Bochner BH; Donat SM; Herr HW; Dalbagni G
J Urol; 2006 Aug; 176(2):482-5. PubMed ID: 16813873
[TBL] [Abstract][Full Text] [Related]
18. Multivariate evaluation of factors affecting recurrence, progression, and survival in patients with superficial bladder cancer treated with intravesical bacillus Calmette-Guérin (Tokyo 172 strain) therapy: significance of concomitant carcinoma in situ.
Takashi M; Wakai K; Hattori T; Furuhashi K; Ono Y; Ohshima S; Ohno Y
Int Urol Nephrol; 2002; 33(1):41-7. PubMed ID: 12090337
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer.
Saint F; Patard JJ; Maille P; Soyeux P; Hoznek A; Salomon L; Abbou CC; Chopin DK
J Urol; 2002 Jan; 167(1):364-7. PubMed ID: 11743357
[TBL] [Abstract][Full Text] [Related]
20. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
